PROCEPT BioRobotics Appoints Chief Financial Officer

PROCEPT BioRobotics has appointed Kevin Waters as chief financial officer (CFO). Waters brings approximately 20 years of finance and medical device industry experience to PROCEPT BioRobotics. He joins the company as it expands commercialization of its AQUABEAM Robotic System, the world’s first surgical robot providing autonomous tissue removal for the treatment of benign prostatic hyperplasia (BPH), or enlarged prostate.
 
“Kevin’s deep industry knowledge and leadership experience in commercial stage organizations make him a valuable addition to the PROCEPT team, as we drive towards making Aquablation therapy with the AQUABEAM Robotic System the standard of care for treating BPH,” said Nikolai Aljuri, Ph.D., PROCEPT BioRobotics founder and CEO. “His appointment rounds out the executive team at PROCEPT, well-positioning the company for strong growth ahead.”
 
Waters most recently served as senior vice president and CFO of Accuray Inc., where he was responsible for global finance, accounting, business development, treasury, investor relations, information technology, as well as the company’s commercial functions under sales operations and revenue management. Prior to Accuray, Waters held financial leadership positions at three publicly traded medical device companies, including Conceptus, Laserscope, and VISX. These companies were all sold to strategic acquirors, generating approximately $3 billion in shareholder value. Waters began his career at PricewaterhouseCoopers LLP.

Waters has a bachelor’s degree in business administration, with a concentration in finance and accounting, from Cal Poly San Luis Obispo.
 
Based in the Silicon Valley, PROCEPT BioRobotics is a privately held surgical robotics company enabling better patient care by developing transformative solutions in urology. The company’s first offering, the AQUABEAM Robotic System delivering Aquablation therapy, is the first U.S. Food and Drug Administration-granted surgical robot providing autonomous tissue removal for the treatment of BPH. Aquablation therapy combines the clarity of real-time, multi-dimensional imaging, autonomous robotics and heat-free waterjet ablation for targeted, controlled and immediate removal of prostate tissue for the treatment of lower urinary tract symptoms (LUTS) caused by BPH. Aquablation therapy offers reproducible outcomes, independent of prostate anatomy and size. The AQUABEAM Robotic System is commercially available in the United States, Canada, Australia, New Zealand and select European markets.